Watchmaker Genomics combines deep domain expertise in protein engineering with enzyme manufacturing to address the demanding quality, performance and scale requirements of high-growth genomics applications. We see our clients as partners and view technical and supply chain challenges as opportunities for mutual success. Watchmaker’s best-in-class scientific competencies enable a disruptive approach to life science partnerships.
Starting from a deep understanding of the underlying molecular biology, Watchmaker Genomics’ solutions improve your experiment, assay and workflow, with scalable supply-chain solutions that provide ISO 13485/molecular-grade enzymes for a range of genomic applications.
Trey applies pioneering methods in directed evolution and enzyme engineering to enable novel genomic applications. As Co-Founder and Chief Technology Officer of Kapa Biosystems, Trey led the company’s global commercial and scientific teams in the development of high-growth, innovative products for next-generation sequencing (NGS), qPCR and PCR. Following the acquisition of Kapa Biosystems by Roche in 2015, Trey served as Vice President of Sequencing and Life Science Commercial Operations for Roche North America. He is listed as an inventor on 3 issued patents and 2 pending patents.
Stephen Picone has extensive experience in enzyme manufacturing and supply chain solutions. As Co-Founder, CEO and Chief Strategy Officer at Enzymatics, Stephen managed the scientific operations, coordinated strategic initiatives and developed the company’s proprietary purification technologies to support high-growth NGS companies. Following the acquisition of Enzymatics by Qiagen, Stephen served as Executive Director of Corporate Development at ArcherDX. Prior to founding Enzymatics, Stephen was a product manager at New England BioLabs, focused on manufacture and quality control of a variety of DNA-modifying enzymes. He is listed as inventor on several patents and patent applications.
Brian Kudlow has a deep understanding of genomic applications and product development. Brian was formerly Vice President of Research and Development at ArcherDX, where he led a team of scientists and software developers in the design, development and launch of the company’s flagship products for RNA/DNA-based cancer genomics, liquid biopsy and immune repertoire profiling. Prior to ArcherDX, Brian was a Senior Scientist at Thermo Fisher Scientific in the Dharmacon business unit (now Dharmacon, a Horizon company) where he developed and commercialized innovative technologies for functional genomics. He is a co-author on over 20 peer-reviewed publications in cell biology, genetics and molecular pathology and is listed as an inventor on 3 patent applications.
Paul has over 20 years of experience as a scientist and entrepreneur developing and commercializing tools in genomics and DNA sequencing. He started his career at the Whitehead Institute as part of the team tasked with sequencing the first human genome. There, he developed technologies for DNA purification and sequencing that formed the basis of his first two companies—Agencourt Biosciences (acquired by Beckman Coulter in 2004) and Agencourt Personal Genomics (acquired by Applied Biosystems in 2006). He then co-founded Kapa Biosystems (2006) to apply novel methods in protein engineering to sequencing. Kapa became a leader in NGS sample preparation before being acquired by Roche in 2015.
Do you like to solve interesting and challenging scientific problems? Our team is passionate about innovation and values collaboration, creativity and scientific rigor. We believe the intersection of biology, engineering and computer science presents exciting opportunities to develop novel technologies that promote research and improve human health. Come join the team!Learn More
Watchmaker Genomics is actively seeking partners that are pushing the limits of molecular biology and genomics. We’re building a technology platform to support and accelerate advances in biology at a time in history when the impact of these discoveries can be felt on a global scale. We’re uniquely suited to apply insights, agility and scalability that benefit high-growth companies of all sizes.Learn More